| Literature DB >> 32394396 |
Koenraad Philippaert1,2, Michael Roden3,4,5, Dmitrij Lisak6, Diones Bueno6, Tomas Jelenik7,8, Konstantin Radyushkin9, Teresa Schacht6, Margot Mesuere1,2, Verena Wüllner6, Ann-Kathrin Herrmann6, Jan Baumgart10, Rudi Vennekens1,2, Axel Methner11.
Abstract
Transmembrane BAX inhibitor motif containing 6 (TMBIM6), also known as Bax inhibitor-1, is an evolutionarily conserved protein involved in endoplasmic reticulum (ER) function. TMBIM6 is an ER Ca2+ leak channel and its deficiency enhances susceptibility to ER stress due to inhibition of the ER stress sensor IRE1α. It was previously shown that TMBIM6 overexpression improves glucose metabolism and that TMBIM6 knockout mice develop obesity. We here examined the metabolic alterations underlying the obese phenotype and subjected TMBIM6 knockout mice to indirect calorimetry and euglycemic-hyperinsulinemic tests with stable isotope dilution to gauge tissue-specific insulin sensitivity. This demonstrated no changes in heat production, food intake, activity or hepatic and peripheral insulin sensitivity. TMBIM6 knockout mice, however, featured a higher glucose-stimulated insulin secretion in vivo as assessed by the hyperglycemic clamp test and hepatic steatosis. This coincided with profound changes in glucose-mediated Ca2+ regulation in isolated pancreatic β cells and increased levels of IRE1α levels but no differences in downstream effects of IRE1α like increased Xbp1 mRNA splicing or Ire1-dependent decay of insulin mRNA in the pancreas. We therefore conclude that lack of TMBIM6 does not affect insulin sensitivity but leads to hyperinsulinemia, which serves to explain the weight gain. TMBIM6-mediated metabolic alterations are mainly caused by its role as a Ca2+ release channel in the ER. KEY MESSAGES: TMBIM6-/- leads to obesity and hepatic steatosis. Food intake and energy expenditure are not changed in TMBIM6-/- mice. No changes in insulin resistance in TMBIM6-/- mice. Increased insulin secretion caused by altered calcium dynamics in β cells.Entities:
Keywords: Bax inhibitor-1; Hepatic Steatosis; Insulin secretion; Obesity; TMBIM6
Mesh:
Substances:
Year: 2020 PMID: 32394396 PMCID: PMC7297831 DOI: 10.1007/s00109-020-01914-x
Source DB: PubMed Journal: J Mol Med (Berl) ISSN: 0946-2716 Impact factor: 4.599
Fig. 1Adult TMBIM6−/− mice are obese and develop hepatic steatosis. a, b Adult but not young TMBIM6−/− mice are significantly heavier than wild-type (WT) littermates. a, b Different cohorts of mice. Obesity correlates with the development of hepatic steatosis shown in c by representative hematoxylin and eosin staining on liver slices of WT and TMBIM6−/− mice: note the increased presence of unstained regions indicating more fat content in the liver slice of the older TMBIM6−/− mice compared to WT mice and the younger groups. Statistical analysis based on the fat content in randomly sampled 0.05-mm2 regions from stained slices in the different conditions (two-way ANOVA with post hoc Bonferroni pairwise comparison). d Transmission electron microscopy. Arrows indicate lipid droplets. Normal distribution was assessed using the Shapiro-Wilk test and significant differences calculated using the Student’s t test, *p < 0.05
Fig. 2TMBIM6−/− mice do not exhibit altered food intake, activity, or heat production. Respiratory exchange ratio (RER), heat production, activity, and food consumption of the indicated number of WT and KO mice were quantitated by indirect calorimetry in dedicated metabolic cages. Dark and light cycles are indicated
Fig. 3No alteration of tissue-specific insulin sensitivity in TMBIM6−/− mice. a Blood glucose levels during the hyperinsulinemic-euglycemic clamps. Steady-state conditions were defined as the last 30 min of the clamp. b Blood glucose levels during basal (6 h fasted) conditions and during the steady state of the clamp. c Plasma insulin levels during basal conditions and at the end of the clamp. d Glucose infusion rates required to maintain euglycemia during hyperinsulinemic clamp (GIRHE). e Average GIRHE during the steady state of the hyperinsulinemic-euglycemic clamps. f GIRHE normalized to the plasma insulin levels at the end of the clamp. g Glucose fluxes calculated from D-[6,6-2H2] glucose dilution during basal (basal endogenous glucose production, bEGP) and insulin-stimulated (endogenous glucose production, EGP; glucose turnover, Rd) conditions. h Percent suppression of EGP by insulin compared to basal conditions. i Percent stimulation of Rd by insulin compared to basal conditions. Data are presented as mean ± SD and individual data points. Statistical testing using the Student’s t test revealed no significant differences
Fig. 4TMBIM6−/− mice show greater glucose-stimulated insulin secretion in vivo. a Blood glucose levels during the hyperglycemic clamps. Steady-state conditions were defined as the last 30 min of the clamp. b Glucose infusion rates required to maintain hyperglycemia (GIRHG). The arrows indicate the time points of blood drawing for measurement of insulin levels during the clamp. c Percent change from baseline in insulin concentration during the hyperglycemic clamp. Data are presented as mean ± SD and individual data points. Normal distribution was assessed with the Shapiro-Wilk test and significant differences calculated using the Student’s t test in b and the Mann-Whitney test in c, *p < 0.05
Fig. 5Altered glucose-induced Ca2+ oscillations in pancreatic islets of TMBIM6−/− mice. a Similar islet size in young and adult KO and WT mice. b Typical slow, mixed, and fast Ca2+ oscillations observed when perfusing pancreatic islets with low (3 mM), high (10 mM) glucose containing solution and with a 30 mM KCl containing solution as indicated. c Dividing the islets from WT and KO mice into slow, fast, and mixed oscillating islets based on the relevant peaks in the Fourier transformed frequency spectrum between 0 and 0.015 Hz (slow) and 0.015 Hz and 0.05 Hz (fast). d Superimposed typical example traces of glucose-induced islet Ca2+ oscillations from WT and KO mice and oscillation frequency represented as oscillations per minute for each islet and mean. e Individual values and mean of the integrated area under the curve of the baseline (100–500 s)-corrected fluorescence ratio trace. f Width of Ca2+ oscillations at 30% of the peak height for the islets of TMBIM6−/− and WT mice of 10 weeks and d 22 weeks. Normal distribution was assessed with the Shapiro-Wilk test and significant differences calculated using the Student’s t test, *p < 0.05
Fig. 6Increased IRE1α levels in TMBIM6−/− mice. a Immunoblotting demonstrating no significant regulation of the ER resident protein SEC62 normalized to α/β-tubulin or protein weight. b Reduced expression of the important ER chaperone BIP (GRP78) and c increased expression of IRE1α in the pancreas from old mice when normalized to SEC62 but not to α/β-tubulin. Size is indicated. Each data point represents data obtained from one mouse. Normal distribution was assessed using the Shapiro-Wilk test and significant differences calculated using the non-parametric Mann-Whitney test, *p < 0.05
Fig. 7No alterations in Xbp1 splicing or Ire1-dependent decay in TMBIM6−/− mice. a Unaltered amounts of spliced and total Xbp1 shown by quantitative RT-PCR using probes specific for unspliced or total (spliced and unspliced) Xbp1. a′ Scheme illustrates the position of primers and probes in regard to the spliced part of Xbp1. b Mouse embryonic fibroblasts treated with 0.5 μM thapsigargin served as positive control for the assay. c Quantitative RT-PCR demonstrating similar mRNA levels of the indicated genes. Each data point represents data obtained from one mouse. Normal distribution was assessed using the Shapiro-Wilk test and significant differences calculated using the non-parametric Mann-Whitney test, *p < 0.05